若生智能
Drug Database
IN

insulin

✓ Approved

MJ Biotech · INSR · 重组蛋白

什么是 insulin？

insulin 是一种重组蛋白，由MJ Biotech研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)。

药物档案

公司MJ Biotech
药物类别重组蛋白
分子靶点INSR
给药途径Injectable (Others)
状态Approved
来源： ClinicalTrials.gov, MJ Biotech

作用机制

分子靶点

insulin 作用于 1 个分子靶点：

INSRinsulin receptor (CD220, HHF5)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

insulin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
InvestigationsGlucose tolerance test abnormal✓ Approved

相关研究文献

PubMedJournal of diabetes science and technology2026-08-05

Real-World Outcomes of Automated Insulin Delivery Use in Hospitalized Adults With Diabetes.

Ruddiman Kathleen R KR, Evans Joni K JK, Aloi Joseph A JA, Usoh Chinenye C et al.

Automated insulin delivery (AID) systems are increasingly used by individuals living with diabetes in the outpatient setting, but data on their safety and effectiveness during hospitalizations remains limited. The objective is to evaluate the use and efficiency of AID systems in hospitalized adults with diabetes. We performed a retrospective cohort study based on electronic health record data from hospital admissions of 316 patients with diabetes using insulin pumps. Automated insulin delivery and continuous glucose monitor use, insulin pump continuation, length of stay (LOS), and glycemic outcomes among the cohort were analyzed. The primary aims of the study were to describe rates of insulin pump continuation and reasons associated with removal, and rates of pump reinitiation. Secondary outcomes included effects of insulin pump removal and prompt endocrinology consultation on inpatient glycemic outcomes and LOS. Insulin pumps were continued in 64.2% of all admissions. The most common reason for pump discontinuation was surgery (30.1%). Length of stay was longer when pumps were removed (8.3 vs 4.7 days, P < .001) and when endocrinology consultation occurred more than 24 hours after admission (P < .001). Insulin pump continuation was associated with lower hyperglycemia (glucose >180 mg/dL) rates without an increase in hypoglycemia (glucose <70 mg/dL) in both critical and noncritical care settings. Continuation of insulin pumps was associated with improvement in hyperglycemia without increased hypoglycemia risk and with shorter LOS in the hospital. Standardized institutional policies including prompt glycemic management team consultation may help expand safe continuation of AID during hospitalizations.

PMID 42554596
阅读全文 →
PubMedPloS one2026-08-05

In vitro evaluation of microfluidic WS6-loaded Eudragit nanoparticles for improving insulin-producing cell differentiation.

Abuarqoub Duaa D, Mohammad Marwa M, Albarghouthi Rand R, Abuoun Mohammad M et al.

This study explores a stem-cell-based approach for diabetes treatment by enhancing the viability and functionality of insulin-producing cells (IPCs) derived from stem cells of the apical papilla (SCAP). Although SCAP can differentiate into IPCs, limited cell survival remains a challenge. To address this, the proliferation enhancer WS6 was incorporated into Eudragit RS100 nanoparticles (NPs) using microfluidics. The WS6-loaded NPs were characterized for size, charge, PDI, morphology, stability, and drug loading. An MTT assay was performed as a preliminary screening method to evaluate the cytocompatibility of blank-NPs and to optimize treatment concentration. SCAP cells were treated with free WS6 or WS6-loaded NPs, and cellular uptake of NPs was evaluated using flow cytometry and fluorescence imaging. Additionally, the viability of treated cells was determined by propidium iodide (PI) and trypan blue. Prior to differentiation, definitive endoderm formation was assessed through SOX17 and FOXA2 expressions. After differentiation into IPCs, maturation markers such as insulin, C-peptide, PDX-1, NKX2.2, and NKX6.1 were examined, and apoptosis assays measured cell viability. Functional insulin secretion was tested using an in vitro glucose-stimulated insulin secretion (GSIS) assay. Results showed that WS6-loaded NPs significantly improved SCAP viability, increased healthy cell percentages, and enhanced IPC maturation. Treated IPCs demonstrated functional insulin secretion and improved glucose regulation. Overall, WS6-loaded NPs represent a promising approach to enhance IPC proliferation and generation for diabetes therapy.

PMID 42550869
阅读全文 →
PubMedFrontiers in immunology2026-08-05

Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles.

Cole Rebecca S RS, Silmon de Monerri Natalie C NC, Lypowy Jacqueline J, Ponce Christopher C et al.

Urinary tract infections, caused primarily by uropathogenic E. coli, are a significant public health burden, affecting approximately 50% of women worldwide. The adhesin FimH is responsible for host receptor binding and is therefore a promising vaccine candidate, but prior studies showed that recombinant monomeric FimH is poorly immunogenic. Here we displayed FimH antigens on the two-component protein nanoparticle I53-50 to generate nanoparticle immunogens that elicit robust levels of receptor-blocking antibodies in mice and non-human primates. We produced nanoparticle immunogens displaying either the FimH lectin domain or a recently reported conformationally stabilized antigen, FimH-DSG, comprising both the lectin and pilin domains. When formulated on aluminum hydroxide, both nanoparticle immunogens elicited similar levels of receptor-blocking activity as a ten-fold higher dose of monomeric FimH-DSG formulated with a potent adjuvant. The improved manufacturability of the stabilized antigen, combined with the ability of nanoparticle display to obviate the need for complex adjuvants, provides important preclinical data for FimH-based vaccines intended to prevent urinary tract infections. More broadly, our data extend the applicability of the I53-50 nanoparticle platform, which to date has been mainly used for displaying viral and protozoan antigens, to bacterial indications.

PMID 42553347
阅读全文 →
PubMedEuropean heart journal. Case reports2026-08-05

Subintimal excimer laser coronary atherectomy (S-ELCA) as a bail-out for device-uncrossable chronic total occlusion: case report.

Elsherif Ahmed A, Fawzy Ameenathul A, Khattak Sophia S, Shahid Farhan F et al.

Chronic total occlusion (CTO) that cannot be crossed with balloons or microcatheters despite successful guidewire passage represent one of the most challenging scenarios in percutaneous coronary intervention (PCI). Excimer laser coronary angioplasty (ELCA) is an established adjunct for device-uncrossable lesions; however, the safety of its application within the subintimal space remains limited. A 67-year-old male with a complex cardiac history, including prior recurrent interventions and coronary artery bypass grafting, was referred for staged PCI of a right coronary artery CTO because of refractory angina (Canadian Cardiovascular Society class III). Following successful antegrade subintimal wire tracking and re-entry using a Stingray balloon, multiple ultra-low-profile balloons and dedicated microcatheters failed to traverse the subintimal-to-true-lumen transition. A 0.9-mm ELCA catheter at 80 mJ/mm2 and 80 Hz was used in the subintimal space without saline flush, successfully creating a traversable channel. Complete revascularization was achieved using six overlapping drug-eluting stents, optimized with intravascular ultrasound guidance. At two-year follow-up, repeat intravascular ultrasound demonstrated vascular healing at the subintimal-re-entry interface. This case demonstrates the potential safety and feasibility of subintimal ELCA (SELCA) as a bail-out for device-uncrossable lesions during antegrade dissection re-entry of CTO-PCI, with the first reported evidence of vascular healing at the subintimal laser site at two-year follow-up.

PMID 42553813
阅读全文 →
PubMedMaterials horizons2026-08-05

Tough, self-healing and recyclable polyurea elastomer with dual dynamic crosslinked networks for sustainable flexible strain sensors.

Guo Yiqin Y, Tang Jingzhi J, Yang Zhipeng Z, Mou Xingyu X et al.

Elastomers integrating self-healing capability, recyclability, and excellent mechanical performance have attracted considerable interest owing to their great application prospects in the emerging fields of soft robots, wearable electronics, and biomedical engineering. Herein, we synthesized a tough, self-healing and recyclable polyurea elastomer through the addition reaction of isophorone diisocyanate with polyether amine and 3,5-diaminobenzoic acid, followed by the incorporation of metal ions to construct dual dynamic crosslinked networks composed of multiple hydrogen bonds and metal-carboxylate coordination bonds. Unlike the Fe3+-coordinated polyurea elastomer, the Zn2+-coordinated polyurea elastomer achieved excellent mechanical performance, with a tensile strength of 10.89 MPa, an elongation at break of 1656% and toughness of 137.40 MJ m-3, which was attributed to the moderate coordination capability and homogeneous dispersion of Zn2+ ions, as confirmed by theoretical simulations and polarized light imaging. Benefiting from the formation of the dual dynamic crosslinked networks, the elastomer demonstrated superior self-healing capability with a healing efficiency of 93.5% at 60 °C for 24 h and remarkable recyclability through hot-press and solvent recycling methods with tensile strength retentions of 80.0% and 99.3% after three recycling cycles, respectively. In addition, a polyurea-elastomer-based tubular flexible strain sensor with liquid metal as a conductive substance for object recognition was highly sensitive, completely recyclable, and capable of self-healing. The findings in this work conceivably represent a new methodology for the preparation of high-performance, functional and sustainable elastomers and flexible sensors.

PMID 42553003
阅读全文 →
PubMedFrontiers in immunology2026-08-05

J2R/F4L deleted oncolytic vaccinia virus synergizes with tumor specific killer (ELANE) promotes antitumor immunity with superior safety.

Huang Yu Y, Wang Liming L, Mei Shan S, Zhao Fei F et al.

Oncolytic virotherapy (OVT) represents a promising approach for cancer treatment, employing oncolytic viruses (OVs) that selectively infect and lyse tumor cells while promoting an antitumor immune microenvironment. Vaccinia virus (VACV) serves as an attractive oncolytic vector due to its favorable safety profile, ease of genetic modification, and inherent tumor selectivity. To enhance both safety and tumor-targeting capability, we constructed a recombinant vaccinia virus, VV-dTF/EE, by deleting the viral J2R and F4L genes and inserting the human neutrophil elastase (ELANE) gene, which exhibits tumor-killing activity. Mechanistic studies evaluated with virus replication selectivity, cell apoptosis, genomic damage, immunogenic cell death, alongside analysis of the immune microenvironment. Efficacy was tested in multiple tumor cell models in vitro and lung cancer models in vivo. In tumor cell lines and mouse tumor models, VV-dTF/EE demonstrated tumor-restricted replication, potent oncolytic effects, and induction of immunogenic cell death. Furthermore, VV-dTF/EE augmented VACV-induced antitumor immunity by increasing CD8+ T cell infiltration and suppressing M2-like macrophage polarization. This VV-dTF/EE revealed tumor-selective replication and killing ability while modifying the tumor immune microenvironment to elicit immunogenic cell death. Our findings highlight a novel strategy for safe and effective tumor immunotherapy through dual-gene deletion and ELANE expression in an oncolytic vaccinia platform.

PMID 42553337
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多insulin